David A. Siegel Oric Pharmaceuticals, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Oric Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 66,500 shares of ORIC stock, worth $532,000. This represents 0.0% of its overall portfolio holdings.
Number of Shares
66,500
Previous 58,200
14.26%
Holding current value
$532,000
Previous $596,000
10.07%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding ORIC
# of Institutions
132Shares Held
67.3MCall Options Held
404KPut Options Held
6.4K-
Nextech Invest Ag5.29MShares$42.3 Million7.95% of portfolio
-
Black Rock Inc. New York, NY4.83MShares$38.6 Million0.0% of portfolio
-
Viking Global Investors LP4.43MShares$35.4 Million0.12% of portfolio
-
Vr Adviser, LLC New York, NY4.39MShares$35.2 Million5.85% of portfolio
-
Alkeon Capital Management LLC New York, NY3.9MShares$31.2 Million0.07% of portfolio
About Oric Pharmaceuticals, Inc.
- Ticker ORIC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,576,700
- Market Cap $317M
- Description
- ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment r...